Total
0
Shares
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald
CEO, Dr Sean Hall
Source: Medlab Clinical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medlab Clinical (MDC) receives a notice of allowance from the United States Patent Office (USPTO) regarding a patent for its trademarked NRGBiotic
  • The formula combines specific probiotics with magnesium orotate to treat and prevent depression, and is already available in Australia
  • The notice of allowance signals a patent for the product may be granted in the US, with Medlab expecting the formality within three to four months
  • CEO Sean Hall says the news is welcome following a successful trial of NRGBiotic at the Queensland University of Technology earlier this month
  • Shares are sitting steady at 18 cents at 3:24 pm AEST

Medlab Clinical (MDC) has been issued with a notice of allowance by the United States Patent Office (USPTO) regarding a patent for its trademarked NRGBiotic.

Based in Sydney, the company's formula aims to help treat and prevent depression. It comprises specific probiotics combined with magnesium orotate and is already available in Australian pharmacies.

The notice of allowance indicates a patent for the treatment can be granted in the US, with Medlab expecting the formality within the next three to four months.

The pending patent will cover the formulation of NRGBiotic, as well as a method for treating, preventing or ameliorating at least one symptom of depression or a depressive disorder, and will be valid through to October 28, 2035.

Medlab CEO Sean Hall said the green light from US Patent Office was welcome news.

"Receiving this notification off the back of successful trial outcomes attests to the robust work Medlab undertakes," Dr Hall said.

"From a commercial aspect, NRGBiotic is a branded line here in Australia, and will now go to our partnering network in the northern hemisphere."

Earlier this month, Medlab reported "significant" mental health findings in a study of the formula at Queensland University of Technology.

Shares were sitting steady at 18 cents apiece at 3:24 pm AEST.

MDC by the numbers
More From The Market Herald
Adherium (ASX:ADR) - CEO, Rick Legleiter - The Market Herald

" Adherium (ASX:ADR) nabs supply contract for AstraZeneca study in US

Adherium (ADR) has been awarded a supply contract for an upcoming clinical study by AstraZeneca in the United States.
Dimerix (ASX:DXB) - MD and CEO, Dr Nina Webster - The Market Herald

" Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended that Dimerix’s (DXB) DMX-200 clinical study in COVID-19 patients be approved.
Antisense Therapeutics (ASX:ANP) - MD and CEO - The Market Herald

" Antisense Therapeutics (ASX:ANP) presents new data, files Australian patent

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.
Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder - The Market Herald

" Sigma Healthcare (ASX:SIG) appoints new CEO

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.